Mayur Ian Somaiya is CFO at NewAmsterdam Pharma Co N.V. (NAMS). They have made 4 open-market trades across 2 companies since 2020, most recently 2026-01-21.
CIK 0001760303
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NAMS | 98,166 | $1.9M |
| TCRR | 3,473 | $5K |
| Total | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-01-22 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.